Aptiv (NYSE:APTV – Free Report) had its price objective lowered by TD Cowen from $95.00 to $74.00 in a research note published on Friday, Benzinga reports. TD Cowen currently has a buy rating on the auto parts company’s stock.
A number of other research analysts have also commented on APTV. Evercore ISI lowered their price objective on Aptiv from $125.00 to $115.00 and set an “outperform” rating on the stock in a report on Monday, July 15th. JPMorgan Chase & Co. boosted their price objective on shares of Aptiv from $107.00 to $113.00 and gave the stock an “overweight” rating in a research note on Monday, October 21st. Morgan Stanley lowered their target price on shares of Aptiv from $70.00 to $68.00 and set an “underweight” rating on the stock in a research note on Wednesday, September 25th. Robert W. Baird cut their target price on shares of Aptiv from $85.00 to $65.00 and set a “neutral” rating for the company in a research report on Friday. Finally, Royal Bank of Canada lowered their price target on Aptiv from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Friday. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Aptiv currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.00.
Check Out Our Latest Stock Analysis on APTV
Aptiv Stock Down 0.8 %
Aptiv (NYSE:APTV – Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The auto parts company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.68 by $0.15. The company had revenue of $4.85 billion for the quarter, compared to analyst estimates of $5.10 billion. Aptiv had a net margin of 12.29% and a return on equity of 14.51%. Aptiv’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.30 EPS. Equities research analysts forecast that Aptiv will post 6.23 EPS for the current fiscal year.
Hedge Funds Weigh In On Aptiv
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Buckingham Capital Management Inc. raised its position in Aptiv by 65.6% in the third quarter. Buckingham Capital Management Inc. now owns 6,676 shares of the auto parts company’s stock worth $481,000 after purchasing an additional 2,645 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Aptiv in the 3rd quarter worth approximately $639,000. State of New Jersey Common Pension Fund D lifted its position in shares of Aptiv by 0.6% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 97,803 shares of the auto parts company’s stock worth $7,043,000 after buying an additional 581 shares during the period. Assetmark Inc. boosted its stake in Aptiv by 15.8% in the 3rd quarter. Assetmark Inc. now owns 3,837 shares of the auto parts company’s stock valued at $276,000 after buying an additional 523 shares in the last quarter. Finally, Equitable Trust Co. grew its position in Aptiv by 11.1% in the third quarter. Equitable Trust Co. now owns 17,392 shares of the auto parts company’s stock valued at $1,252,000 after acquiring an additional 1,734 shares during the period. 94.21% of the stock is owned by institutional investors.
About Aptiv
Aptiv PLC engages in design, manufacture, and sale of vehicle components in North America, Europe, Middle East, Africa, the Asia Pacific, South America, and internationally. The company provides electrical, electronic, and safety technology solutions to the automotive and commercial vehicle markets. It operates through two segments, Signal and Power Solutions, and Advanced Safety and User Experience.
Featured Articles
- Five stocks we like better than Aptiv
- What is a support level?
- Intel: Is Now the Time to Be Brave?Â
- With Risk Tolerance, One Size Does Not Fit All
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Aptiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptiv and related companies with MarketBeat.com's FREE daily email newsletter.